Skip to main content
TipRanks
Go Ultimate75% OFF

Vitalhub (VHIBF) AI Stock Analysis

2 Followers
VHIBF

Vitalhub

(Other OTC:VHIBF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Revenue GrowthStrong ARR and recurring-revenue growth supports greater visibility than project-based sales alone. A larger contracted revenue base can improve retention economics, stabilize planning, and provide a durable platform for cross-selling additional healthcare workflow and care-coordination products.
Negative Factors
SHREWD Customer UncertaintyThe SHREWD situation creates a material risk to recurring revenue durability because management cannot yet determine which accounts may be affected. Continued suspensions or reversals could reduce ARR, delay growth recovery, and require the broader portfolio to offset a meaningful product-specific shortfall.

Vitalhub (VHIBF) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%VHIBF-28.36%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$443.37M
Dividend Yield
―
Average Volume (3M)
18.22K
Price to Earnings (P/E)
40.2
Beta (1Y)
0.90
Revenue Growth
30.10%
EPS Growth
236.27%
Country
US
Employees
700
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Vitalhub Business Overview & Revenue Model

Company Description

Vitalhub Corp., through its subsidiaries, provides innovative technological solutions to health and human service providers internationally, specifically catering to markets in Canada, the United States, the United Kingdom, Australia, and Western Asi...

Vitalhub Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-17.71%|Next Earnings Date:May 24, 2019
Earnings Call SentimentPositive

The call was predominantly positive, supported by 14% ARR growth, 9% recurring revenue growth, a two-year-high 27% adjusted EBITDA margin, a return to net income, 69% growth in year-to-date operating cash flow, a debt-free balance sheet, successful acquisition integration, strong services backlog, and multiple AI and platform initiatives. The principal challenges were flat total revenue, lower perpetual and services revenue, a decline in gross margin, higher G&A, and uncertainty surrounding SHREWD and the NHS FDP program. Management indicated that the rest of the business remains strong and that these challenges are being offset by other growth initiatives.

Positive Updates

ARR Growth and Recurring Revenue Expansion
Annual recurring revenue reached $107.2 million at September, an increase of 14% over the prior year, including 8% organic growth and approximately $4.5 million from the Buddy Healthcare acquisition. Recurring revenues increased 9% year-over-year.

Negative Updates

Total Revenue Was Flat and Variable Revenue Declined
Total revenue was $31.9 million, in line with the prior-year period. Perpetual license revenue declined to $100,000 from $500,000, while services, hardware and other revenue declined to $3.7 million from $5.5 million. Management said services revenue was seasonally lighter over the summer and affected by the timing of milestone-based revenue recognition.

Company Guidance

VitalHub said services revenue should tick up in Q4, with “a lot more milestones” expected to be hit than in Q3, and that Q4 “should get there”; it guides itself to 27% adjusted EBITDA margin, expects to “sustain, if not improve that number on a quarter-over-quarter basis,” and said Buddy Healthcare should reach its level in “6 months to 1 year” through “a little bit of cost reduction and revenue generation.” Ontario work is expected to continue through 2027, Novari should reach “well over the $20 million in ARR numbers,” Strata has “another $3 million to $5 million in the pipeline” over the next couple of years, and AI products could add “about $30 million, $40 million of TAM” on top of the installed base. The company believes it can recapture Rule of 40 status in 2027, with margins continuing to increase, while Attend Anywhere could “decline moderately,” although new deals may offset some of that; SHREWD represents “7%, 8% of our ARR number,” and there is “close to about $10 million or so-ish” of SHREWD revenue still out there.

Vitalhub Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VHIBF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:NDATTSE:NDAT45NeutralCAD 413.27K-16.67-49.83%――0.00%
TSE:ADKTSE:ADK43NeutralCAD 39.74M-7.999999.00%―-36.92%13.03%
TSE:CHSTSE:CHS42NeutralCAD 10.15M-1.4764.52%―7.63%-106.03%
TSE:UDOCTSE:UDOC41NeutralCAD 4.32M-1.33355.56%―614.03%51.97%

* Healthcare Sector Average

Performance Comparison

0%500%1000%VHIBFTSE:ADKTSE:NDATTSE:CHSTSE:UDOCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VHIBF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VHIBFVitalhub Corp.4.61-1.69-26.85%
TSE:ADKDiagnos Inc0.330.0517.86%
TSE:NDATnDatalyze Corp0.01-0.00-33.33%
TSE:CHSComprehensive Healthcare Systems Inc0.35-0.17-32.69%
TSE:UDOCUnidoc Health Corp.0.05-0.15-75.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.